NFE2L2 and non-small cell lung carcinoma: Our biochemical, structural, and therapeutic model findings collectively reveal a proline-dependent regulatory mechanism for NRF2 stability, and we demonstrate that this mechanism can be pharmacologically targeted in NSCLC with NRF2 hyperactivation.